The invention relates to a pre-filled injection device comprising an enclosed glass cartridge having a distal neck portion with a circumferential shoulder portion, and a proximal end portion with an opening surrounded by a proximal circumferential rim. A piston rod is adapted to move a plunger inside the cartridge. The two-part cartridge enclosure enclosing the glass cartridge comprises a distal section comprising a distal support structure engaging the circumferential shoulder portion of the cartridge and a proximal section comprising a proximal support structure engaging the proximal circumferential rim of the cartridge. The proximal support structure comprises support ribs pointing inwardly into the cartridge enclosure to engage the cartridge, and which support ribs are non-perpendicular and resilient.
This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
Lipid-conjugated oligonucleotide are provided herein that inhibit or reduce expression of target genes. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with an RNAi trigger induced decrease in target gene expression.
A computing system for providing a titration dose guidance a subject to treat diabetes, the system comprises one or more processors and a memory, the memory comprising instructions for executing by the one or more processors: (i) a for the subject representative prediction algorithm adapted to calculate the mean and the variance of the resulting fasting blood glucose value (FBG) for the subject as a function of the size of an injected dose of insulin, the prediction algorithm being adaptive in response to obtained FBG and insulin dose size data for the subject, and (ii) a probability algorithm adapted to, based on predicted mean and variance FBG values and an FBG target range, calculate as a function of insulin dose size the probability of hypoglycaemia for the subject.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
The present invention relates to improved medical therapies for all forms and stages of dementia involving administration of (i) GLP-1 receptor agonists to subjects with metabolic syndrome or (ii) semaglutide.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present invention relates to compounds (e.g. ISVDs, polypeptides, polypeptide derivatives) capable of binding to Interleukin-6 (IL-6) and their use in the treatment of inflammatory diseases such as, e.g. cardiovascular disease (CVD).
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
9.
COMPOSITIONS AND METHODS FOR INHIBITING KETOHEXOKINASE (KHK)
Oligonucleotides are provided herein that inhibit KHK expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with KHK expression.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The present invention relates to compounds (e.g. ISVDs, polypeptides, polypeptide derivatives) capable of binding to Interleukin-6 (IL-6) and their use in the treatment of inflammatory diseases such as, e.g. cardiovascular disease (CVD).
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A polypeptide comprising a binder, the binder having a binding affinity to Sortilin-1 (Sort1) receptor and constructs thereof. The Sort1 binder capable of binding to the Sort1 receptor when the Sort1 receptor is in a protonated state, and wherein the polypeptide is further capable of being released from the Sort1 receptor when the Sort1 receptor is in a deprotonated state. The constructs a binder moiety and a cargo moiety, the cargo moiety linked to the binder moiety via a linker, the binder moiety being capable of binding to a Sortilin-1 (Sort1) receptor. The Sort1 binder and/or the construct comprising the Sort1 binder of use in promoting internalization a cargo, internalization of a therapeutic agent or extracellular protein degradation.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A method for providing a titration insulin dose guidance recommendation (DGR) for a diabetic patient is provided, wherein a plurality of dose guidance algorithms (DGAs) adapted to calculate a dose recommendation for the patient is provided. Each DGA is characterized by a level of aggressiveness (LA) and a corresponding level of required data quality for a blood glucose history (BGH). When a DGR is requested by the patient one of the DGAs is selected based on a determined BGH data quality level for a BGH data set comprising BG values for a given period of lapsed time. The determination is based one or more of the following BGH properties: (i) number of measured BG values, (ii) variability of measured BG values, and (iii) qualifier type for the BG measurements. The qualifier type may comprise fasting BG measurements, non-fasting BG measurements, and CGM measurements.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
The present document relates to tetrahydropyridazine compounds, pharmaceutical compositions comprising the same and their use in the treatment or prevention of diseases and disorders associated with the cannabinoid CB1 receptor. For example, the tetrahydropyridazine compounds, or a tautomeric form and/or salt thereof, are of Formula I, wherein R1 to R4, X1, and a are as defined herein.
The present document relates to tetrahydropyridazine compounds, pharmaceutical compositions comprising the same and their use in the treatment or prevention of diseases and disorders associated with the cannabinoid CB1 receptor. For example, the tetrahydropyridazine compounds, or a tautomeric form and/or salt thereof, are of Formula I, wherein R1 to R4, X1, and a are as defined herein.
C07D 237/04 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
17.
ENRICHMENT OF NKX6.1 AND C-PEPTIDE CO-EXPRESSING CELLS DERIVED IN VITRO FROM STEM CELLS
The present invention relates to method of enriching NKX6.1 and C-peptide co-expressing cell aggregates derived in vitro from stem cells said method comprising the steps of dissociating the endocrine cell aggregates into single cells, treating the single cells with cryopreservation medium and lowering temperature to obtain cryopreserved cells, thawing the cryopreserved cells; and re-aggregating the cells obtained after thawing into endocrine cells.
The present invention relates to a photochemical process for the manufacturing of a C-terminal α-amide, which are a class of compounds that represent up to half of all biologically relevant peptide hormones. The invention provides mild, broad in scope, economically efficient process, which is suitable for large scale manufacturing.
Antibodies that are capable of specifically binding and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils with both good affinity and low viscosity at clinically relevant concentrations are described. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
20.
PHARMACEUTICAL COMPOSITIONS OF INSULIN DERIVATIVES
The present invention relates to a composition comprising an insulin derivative comprising at least one aryl boronic acid or aryl boroxol; and methionine, as well as the use hereof in the treatment of diabetes, including diabetes of Type 1 and diabetes of Type 2.
09 - Scientific and electric apparatus and instruments
35 - Advertising and business services
Goods & Services
Recorded computer software for predicting medical treatment effects.. Promotion via a website, of software that predicts the effects of medical treatment.
09 - Scientific and electric apparatus and instruments
41 - Education, entertainment, sporting and cultural services
Goods & Services
Electronic publications, namely, leaflets, books, booklets, handouts, magazines as well as medical, instructional and teaching material in the field of obesity; electronic reports featuring results from clinical trials and studies in the field of prevention and treatment of obesity; software applications for use with mobile devices for monitoring and the management of obesity; computer hardware and software, for use with medical injection devices for collecting, transmitting, and displaying medical data; medical software for the management of obesity; Software intended for medical purposes that perform these purposes without being part of a hardware medical device; Downloadable software in the nature of a mobile application for the treatment of obesity, for use by patients and healthcare professionals. Providing information in the field of obesity and weight management; providing information in the field of obesity and weight management via a website.
09 - Scientific and electric apparatus and instruments
16 - Paper, cardboard and goods made from these materials
35 - Advertising and business services
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Downloadable software in the nature of mobile applications for the treatment of medical conditions, for use by patients and healthcare professionals; downloadable software from websites for use by patients and healthcare professionals for the treatment of medical conditions.. Printed material related to treatment of medical conditions.. Promoting public awareness about medical conditions. Educational services, namely, educational programmes, online electronic publications, reports, newsletters, and articles, online coaching and training services for patients and healthcare professionals related to the treatment of medical conditions.. Providing information in the field of management of medical conditions; providing information in the field of management of medical conditions via a website..
The present invention relates to improved procoagulant antibodies including bispecific antibodies capable of binding to coagulation Factor IX (FIX) or the activated form thereof Factor IXa (FIXa) and optionally Factor X (FX) and the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A.
The present invention relates to a method for directing differentiation of neural cells into neurons by obtaining a cell population comprising neural cells and contacting the cell population with an inhibitor of NOTCH signaling, wherein the inhibitor of NOTCH signaling is selected from LY411575, Avagacestat, Dibenzazepine, and PF-03084014.
The present invention provides ISVD polypeptide derivatives capable of binding coagulation Factor IX(a) and Factor X(a) which are highly potent and provide a sufficiently long half-life such to allow for effective subcutaneous—as well as peroral administration. The ISVD polypeptides derivatives disclosed herein are thus suitable for treatment of haemophilia A, haemophilia A with inhibitors and acquired haemophilia A by various routes of administration including subcutaneous and peroral administration.
The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy.
The present invention is directed to use of the GLP-1 receptor agonist semaglutide in medical therapy for the treatment of heart failure with preserved ejection fraction (HFpEF).
The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising a stabilizer such as histidine, their preparation, kits comprising such compositions as well as medical uses thereof.
Disclosed herein is a preserved liquid pharmaceutical formulation comprising an amylin receptor agonist, a GLP-1 receptor agonist, a cyclodextrin comprising hydroxypropyl substitutions and one or more preservatives. Said co-formulation may be used for the medical treatment of subjects with overweight or obesity, with or without associated co-morbidities; diabetes, with or without associated comorbidities; and cardiovascular diseases.
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of diabetes;
pharmaceutical preparations for weight reduction and long
term weight loss maintenance; pharmaceutical preparations
for the treatment of cardiovascular diseases.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of diabetes;
pharmaceutical preparations for weight reduction and long
term weight loss maintenance; pharmaceutical preparations
for the treatment of cardiovascular diseases.
The invention relates to fusion proteins comprising a GLP-1 polypeptide and an FGF21 polypeptide separated by spacers. The invention also relates to fusion compounds comprising the fusion proteins and at least one substituent. The invention also relates to the pharmaceutical use of the fusion compounds.
A drug delivery assembly comprising a drug delivery device and a thereon mountable needle unit. The needle unit comprises a needle hub with a hollow needle having a pointed distal end protruding from the needle hub, and a shield in which the needle hub is fully or partly arranged, the shield being axially moveable relative to the needle hub between an extended position in which the shield axially covers the needle distal end, and a retracted position in which the needle distal end protrudes from the shield. The needle unit further comprises coupling means allowing the needle unit to be mounted on the drug delivery device, the coupling means being actuatable between (i) a lock state in which a mounted needle unit cannot be removed from the drug delivery device, and (ii) an actuated release state in which the needle unit can be removed from the drug delivery device.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/34 - Constructions for connecting the needle
A61M 5/50 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile
A61M 5/24 - Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or cartridges, e.g. automatic
A drug delivery assembly comprising a drug-filled cartridge, an actuatable drug-expelling mechanism, a needle hub with a needle protruding from the needle hub, and a shield in which the needle hub is fully or partly arranged, the shield being axially moveable relative to the needle hub between an extended position in which the shield axially covers the needle, and a retracted position in which the needle protrudes from the shield corresponding to a needle free length. The shield is mounted non-rotatable relative to the housing, the needle hub being rotatable relative to the shield and thus to the housing. The needle hub is rotated relative to the shield when the shield is moved from its retracted to its extended position, wherein rotational movement of the needle hub takes place after at least half of the needle free length has been covered by the shield.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/34 - Constructions for connecting the needle
A61M 5/50 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
39.
SHIELDED NEEDLE UNIT WITH ACTUATABLE MOUNTING FEATURE
A drug delivery assembly comprising a drug delivery device and a thereon mountable needle unit. The needle unit comprises a needle hub with a hollow needle having a pointed distal end protruding from the needle hub, and a shield in which the needle hub is fully or partly arranged, the shield being axially moveable relative to the needle hub between an extended position in which the shield axially covers the needle distal end, and a retracted position in which the needle distal end protrudes from the shield. The needle unit further comprises coupling means allowing the needle unit to be mounted on the drug delivery device, the coupling means being actuatable between an initial mounting state in which the needle unit can be mounted on the drug delivery device, and a lock state in which a mounted needle unit cannot be removed from 10 the drug delivery device.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/34 - Constructions for connecting the needle
A61M 5/50 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
40.
SHIELDED NEEDLE UNIT WITH ACTUATABLE CONTAINER COUPLING
A needle assembly comprising a needle unit and a container therefor. The needle unit comprises a needle hub in which a distally protruding needle is mounted, and a shield in which the needle hub is arranged. The shield is axially moveable between an extended position in which the shield axially covers the needle distal end, and a retracted position in which the needle distal end protrudes from the shield, as well as coupling means allowing the needle unit to be mounted on a drug delivery device. The assembly comprises a snap coupling between the container and the shield, the snap coupling being actuatable between an engaged first state in which the needle unit can be removed from the container using a first amount of force, and a second engaged state in which the needle unit can be removed from the container using a second higher amount of force.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/34 - Constructions for connecting the needle
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
41.
DRUG DELIVERY ASSEMBLY WITH DOUBLE-DOSE PREVENTION
A drug delivery assembly comprises a drug delivery device and a thereon mountable needle unit. The drug delivery device comprises an actuatable spring-driven expelling mechanism for expelling an amount of drug. The needle unit comprises a shield in which a hub with a needle is arranged, the shield being axially moveable relative to the hub between an extended position in which the shield axially covers the needle distal end, and a retracted position in which the needle distal end protrudes from the shield. Shield locking means is actuated when the shield is moved from the retracted to the extended position, the actuated shield locking means pre- venting retraction of the shield. The shield is adapted to actuate the expelling mechanism ac- tuation means when the shield is moved from the extended position to the retracted position, whereby double-actuation of the expelling mechanism with the same needle unit mounted is prevented.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/34 - Constructions for connecting the needle
A61M 5/50 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A drug delivery assembly comprising a drug delivery device and a thereon mountable needle unit. The needle unit comprises a shield in which a needle hub with a needle is arranged, the shield being axially moveable between an extended position in which the shield axially covers the needle distal end, and a retracted position in which the needle distal end protrudes from the shield, the shield comprising a proximal skirt portion. The drug delivery device comprises a circumferential space adapted to receive the shield. The circumferential space and the shield skirt portion have corresponding non-circular configurations allowing the shield skirt portion to be axially received in the circumferential space in one or more pre-determined rotational mounting positions. Corresponding coupling means on the hub respectively the drug delivery device allows needle unit to be mounted on the drug delivery device in any of the pre-determined rotational positions.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/34 - Constructions for connecting the needle
A61M 5/50 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
43.
METHOD FOR PROVIDING A CELL POPULATION ENRICHED IN NEURONS AND PRECURSORS THEREOF
The present invention relates to a method for providing a cell population enriched in neurons and/or precursors thereof, comprising the steps of obtaining a cell population comprising neuron precursors, and selecting cells positive indicative of whether a cell has high propensity for developing into a neuron.
The invention relates to a long-acting growth hormone receptor antagonist comprising a growth hormone variant and an albumin binding moiety. Further described are methods of preparing said compound and use thereof in medicine e.g., for the treatment of acromegaly.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 38/27 - Growth hormone [GH], i.e. somatotropin
A61P 5/02 - Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
45.
AUTOMATIC INJECTION DEVICE WITH A TOP RELEASE MECHANISM
The present invention relates to a handheld mechanical injection device by which set doses of a liquid medicament can be injected from a medical reservoir. The medicament is expelled through an injection needle by release of a power reservoir in the device, the power reservoir being fully or partially released by actuation of a user operable release member being positioned at or near an upper end of the injection device, the upper end being that end of the injection device which is opposite the injection needle.
The present invention provides a dose delivery device (1, 100, 200, 300, 400) comprising: a variable volume reservoir (10, 110, 210, 310, 410) holding a pharmaceutical suspension and comprising an outlet (12, 112, 212, 312, 412), a dose expelling mechanism adapted for activation to expel a volume of the pharmaceutical suspension through the outlet (12, 112, 5 212, 312, 412), and a dose preparation system comprising a preparation member (30, 130, 230, 330, 430) operable prior to activation of the dose expelling mechanism to enable administration of the volume of the pharmaceutical suspension to a subject, wherein the dose preparation system further comprises an agitation member (40, 140, 240, 340, 440) capable of agitating relative motion with respect to the variable volume reservoir (10, 110, 210, 310, 10 410), the agitating relative motion causing a re-suspending agitation of the pharmaceutical suspension, and wherein the agitation member (40, 140, 240, 340, 440) is operatively coupled with the preparation member (30, 130, 230, 330, 430) and configured to undergo said agitating relative motion in response to the operation of the preparation member (30, 130, 230, 330, 430).
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
The present invention relates to novel insulin derivatives and their use in the treatment or prevention of medical conditions relating to diabetes. The insulin derivatives are glucose sensitive and display glucose-sensitive albumin binding. The insulin derivatives have a long half-life. The invention also relates to novel intermediates. Finally, the invention provides a pharmaceutical composition comprising the insulin derivatives of the invention and the use of such a composition in the treatment or prevention of medical conditions relating to diabetes.
An ingestible device may include one or more deployable limbs configured to orient the ingestible device in a desired orientation. The one or more limbs may be attached to body of the device and wrap around the device in an initial configuration (e.g., prior to deployment of the one or more limbs). The one or more limbs may be configured to deploy when exposed to a predetermined condition. Once the predetermined condition is met, the one or more limbs may extend outwards away from the body such that the one or more deployed limbs serve to orient the ingestible device.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of diabetes; pharmaceutical preparations for weight reduction and long term weight loss maintenance; pharmaceutical preparations for the treatment of cardiovascular diseases.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of diabetes; pharmaceutical preparations for weight reduction and long term weight loss maintenance; pharmaceutical preparations for the treatment of cardiovascular diseases.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of diabetes; Pharmaceutical preparations for weight reduction and long term weight loss maintenance; Pharmaceutical preparations for the treatment of cardiovascular diseases..
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of diabetes; Pharmaceutical preparations for weight reduction and long term weight loss maintenance; Pharmaceutical preparations for the treatment of cardiovascular diseases..
54.
COMPOSITIONS AND METHODS FOR SITE-DIRECTED MUTAGENESIS
The present disclosure provides improved genome editing compositions and methods for editing a double-strand DNA target site. The disclosure further provides genome edited cells produced by the compositions and methods described.
The invention relates to a tablet comprising a salt of N-(8-(2-hydroxy benzoyl)amino)caprylic acid. The invention further relates to processes for the preparation such a tablet, and its use in medicine.
The invention relates to fusion proteins comprising a GLP-1 polypeptide and an FGF21 polypeptide separated by spacers. The invention also relates to fusion compounds comprising the fusion proteins and at least one substituent. The invention also relates to the pharmaceutical use of the fusion compounds.
The invention relates to a method of identifying one or more caudal ventral midbrain (cVM) progenitor cells by measuring the presence and/or amount of adenomatosis polyposis coli down-regulated 1 (APCDD1) expressed by the one or more cells. The invention also provides methods of enriching cVM cells, uses of said cells in the treatment of disease, use of APCDD1 as a biomarker, and kits.
Oligonucleotides are provided herein that inhibit TMPRSS6 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with hepcidin deficiency or suppression.
A capsule device (100), comprising: a) a capsule housing (110, 120) having proximal and distal ends and defining a main axis, the capsule housing comprising a plurality of retainer portions (113a) distributed around the main axis, and b) an actuation mechanism (140, 150) operable between a pre-actuation configuration and an actuating configuration, wherein the actuation mechanism (140, 150) comprises: b1) an actuation member (150) configured for axial distal movement, the actuation member (150) comprising a base portion (151) and a plurality of radially deflectable latch arms (153) extending proximally therefrom, wherein each latch arm (153) defines a radially inwards facing latch surface (153b) being inclined with respect to the axis and a radially outwards facing latch surface (153a) in retaining engagement with a respective retainer portion (113a) of the capsule housing (110, 120), b2) a drive spring (140) exerting mechanical load onto the actuation member (150) for driving the actuation member axially in the distal direction, and b3) a dissolvable latch support (160) having radially outwards facing surfaces (163b) being inclined relative to the axis, wherein the dissolvable latch support (160) is arranged centrally on-axis and wherein the plurality of radially deflectable latch arms (163) are distributed around the main axis so that each latch arm (163) is releasably retained radially between a respective one of said inclined outwards facing surfaces (163b) of the dissolvable latch support (160) and a respective one the retainer portions (113a).
A drug delivery device (100, 300) for delivering a medicament, wherein the device comprises an insertion controlled needle cannula (224, 424), wherein the drug delivery device comprises: a retaining structure (130, 136, 350, 430) axially locked to the housing and adapted for retaining the hub (225, 425) in the proximal position, a pulling structure (230, 320) axially locked to the shield (110, 310) and adapted for being disengaged from the hub (225, 425), in a decouple state, whereby the pulling structure is movable relative to the hub (225, 425), and wherein the pulling structure (230, 320) is further adapted for engaging the hub, in a coupled state, whereby the pulling structure is movable together with the hub, wherein the retaining structure and the pulling structure are operatively connected to the shield (110, 310) and the needle assembly (220, 420) in the active position. Thereby, the drug delivery device provides a needle insertion sequence control mechanism ensuring that the distal end of the cannula is covered before the proximal end of the cannula is pulled out from the reservoir.
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
65.
Combination Therapy for Treatment of Liver Disease
The present disclosure relates to a method of treating non-alcoholic steatohepatitis (NASH) comprising administering to a subject with NASH a combination therapy comprising semaglutide, firsocostat, and/or cilofexor.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The invention concerns a process for preparing a pharmaceutical formulation comprising an insulin derivative, wherein the process comprises dissolving an insulin derivative in water, adjusting the pH of the solution to a pH above 7.2, adding a zinc solution while stirring continuously and adjusting the pH to the target pH of the formulation.
A drug delivery device (100, 300) for delivering a plurality of doses of a medicament, wherein a needle shield (110, 310) is operationally coupled to a hub driving structure (210, 430), a active needle assembly (220, 420), a pulling structure (230, 320) and a support structure (136, 336, 338, 350) such that the operation of the needle shield is adapted to drive the active needle assembly (220, 420) to the proximal position of the active needle assembly (220, 420), before the needle shield (110, 310) can reach the proximal position of the needle shield (220, 420), whereby fluid connection can be establish before the drive mechanism can be activated.
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
1. A drug delivery device (100) comprising: a) a drug chamber (B) configured to accommodate a drug substance, the drug chamber (B) leading to a drug delivery opening (195), b) an actuation chamber (A), c) a gas generator (140, 142) configured for being actuated to generate pressurized gas in the actuation chamber (A) for exerting mechanical load on the drug substance in the drug chamber (B) to thereby cause delivery of the drug substance through the drug delivery opening (195), and d) a trigger arrangement (170, 180, 129) initially preventing the pressurized gas from said delivery but allowing said delivery upon gas pressure in the actuation chamber (A) reaching a threshold gas pressure level, wherein the trigger arrangement comprises: d1) a trigger member (170) arranged for displacement from a low-pressure position to a high-pressure position, and d2) a compliant device (180) providing a gradually increasing counter force on the trigger member (170) as the trigger member moves from the low-pressure position to the high-pressure position, wherein the trigger member (170) is adapted to move, due to generated gas, from the low-pressure position in which no mechanical load is exerted by pressurized gas to cause delivery of the drug substance to the high-pressure position in which said mechanical load is allowed to cause delivery of the drug substance through the drug delivery opening (195).
A system comprising RGB and UV light emitting means and RGB light sensor means adapted to measure and differentiate between colours having a given minimum colour difference, as well as first and second colour identifiers having a colour difference below the minimum. One of the colour identifiers comprises a light transforming component adapted to emit additional RGB light when subjected to UV light emitted by the UV light emitting means providing an enhanced RGB colour difference above the minimum colour difference between the RGB light emitted from the first and second colour identifiers when subjected to the combined light from the RGB and UV light emitting means, this allowing the RGB light sensor means to differentiate between the colours of the first respectively the second colour identifier.
The present invention relates to a method of making sodium N-(8-2-Hydroxybenzoyl)amino capry late form A. SNAC polymorphic form A having improved stability and the use of said SNAC polymorphic form A in a solid pharmaceutical dosage form
C07C 235/60 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho- position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
The present disclosure relates to oligonucleotides for selective reduction of levels of target RNA expression and/or proteins expressed in glial cells, and related methods of delivering such oligonucleotides into glial cells.
A capsule administering assembly (100, 100′) comprising an ingestible capsule (200, 200′) for delivery of a mixed drug product to a subject user, and a capsule accessory device (300, 300′), wherein the ingestible capsule is operable from a first attached state where the ingestible capsule (200, 200′) is coupled relative to the capsule accessory device (300, 300′), and a second detached state wherein the ingestible capsule (200, 200′) is detached from the capsule accessory device (300, 300′) to permit ingestion of the ingestible capsule. The capsule administering assembly (100, 100′) comprises a first reservoir (231) holding a first drug component (A) and a second reservoir (332, 362), the second reservoir (332, 362) holding a second drug component (B).
The invention relates to a pre-filled single dose injection device expelling one single dose of a predetermined fixed volume with an embedded cartridge wherein a piston rod has a predetermined travel distance and wherein the position of the travel distance of the piston rod relatively to a housing structure securing the cartridge is individually adjustable for each individual injection device.
Oligonucleotide conjugates are provided herein that inhibit or reduce expression of target genes in the neurons of the central nervous system. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with expression of a neuronal target gene in the CNS.
The invention relates to a compound comprising a GLP-1 receptor agonist and an amylin receptor agonist. The invention also relates to a pharmaceutical formulation, suitable for but not limited to oral administration, which comprises such a compound. The compound and pharmaceutical formulation comprising it may be used for the medical treatment of subjects with overweight, obesity and associated co-morbidities.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
The present invention relates to solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine.
A self-righting ingestible capsule comprising: a) a capsule housing (110, 120) defining a central axis and having proximal and distal ends, b) a sealing compartment (A) within the capsule housing (110, 120) accommodating a solid dose member (130), and comprising a distal exit port (124), c) an actuation compartment (B) fluidically isolated from the scaling compartment (A), d) an actuation member (150) at least partially accommodated in the actuation compartment (B) and arranged for axial displacement thereby moving the dose member (130) distally through the distal exit port (124), e) a helical spring (140) for powering the actuation member (150) in a distal direction, f) a latch component (152) coupled to the actuation member (150) for releasably maintaining the actuation member latched in a proximal position, and g) a dissolvable latch support (160) disposed in the actuation compartment (B), wherein the dissolvable latch support maintains latching of the actuation member (150) in the proximal position by supporting the latch component
The invention relates to a compound comprising an amylin receptor agonist. The invention also relates to a pharmaceutical composition, suitable for but not limited to oral administration, which comprises such a compound. The compound and pharmaceutical composition comprising it may be used for the medical treatment of subjects with overweight, obesity and associated co-morbidities.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A method of estimating insulin on board (IOB) for a given glucose sensitive insulin (GSI) in a subject is provided. The method comprises the steps (i) for the given GSI, providing at least one rate constant (rc) as function of glucose concentration (rc(G)), (ii) providing for a period of time a continuous blood glucose log G(t) from the subject, (iii) providing for the period of time 5 an insulin dose log I(t) from the subject, (iv) based on rc(G) and G(t), calculating for each rc a rate constant as function of time (rc(t)), and (v) based on the at least one rc(t) and I(t) and using an estimating algorithm, calculating an estimated IOB for the subject.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.01% (w/w) phenol, their preparation, kits comprising such compositions as well as uses thereof.
The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
